جستجوی مقالات مرتبط با کلیدواژه "mycoplasma pneumonia" در نشریات گروه "پزشکی"

Mycoplasma pneumoniae pneumonia (MPP) is common in pediatric patients. Many studies showed that recurrent respiratory tract infections (RRTIs) are common in the year following treatment of MPP in infants, but the factors associated with the occurrence of RRTIs are rarely reported. Therefore, the present study aimed to identify these factors.

This retrospective observational study included infants (< one year) who were clinically treated for MPP from January 2015 to December 2018. Clinical features and relevant data were collected on admission. The cases of the occurrence of RRTIs and the presence of related factors after one year of follow-up were investigated by questionnaires. The questionnaires contained the number of upper respiratory infections, tracheobronchitis, and pneumonia, the titers and course of MP-IgG and positive IgM antibody, eczema, pet ownership, interior decoration, inhaled or ingested allergens, exposure to environmental tobacco smoke, and gastrointestinal function. Independent significant risk factors for RRTIs were identified using binary logistic regression.

A total of 300 MPP cases were included, among which RRTIs occurred in 134 (44.7%) cases in the year following MPP treatment. Binary logistic regression analysis showed that a history of prematurity (OR = 6.336, 95% CI: 2.337 - 17.116, P ≤ 0.001), a history of exposure to inhaled or ingested allergens (OR = 2.527, 95% CI: 1.289 - 4.956, P = 0.007), and co-infection involving Chlamydia pneumoniae (OR = 2.787, 95% CI: 1.145 - 6.784, P = 0.024) were significantly and positively associated with RRTIs after MPP, while age (OR = 0.894, 95% CI: 0.825 - 0.970, P = 0.007) showed a negative correlation with RRTIs.

RRTIs in the year following clinical treatment of MPP in infants are relatively common and significantly associated with the patient’s age, history of prematurity, history of exposure to inhaled or ingested allergens, and C. pneumoniae co-infection. Thus, these factors should be carefully assessed in pediatric MPP cases to predict the risk of RRTIs and appropriately manage the patient.

 Early differential diagnosis of coronavirus disease 2019 (COVID-19) and Mycoplasma Pneumonia (MP) are hampered by non-specific symptoms, the lack of rapid responding laboratory measures and the presence of family aggregation. Chest computed tomography (CT) plays a significant role to detect the distribution, density and morphology of lesions caused by either COVID-19 or MP.

 To compare the symptoms, laboratory parameters, and chest CT results of adults with COVID-19 and MP and to assess the use of these findings in the differential diagnosis of these diseases.

 The initial clinical manifestations, laboratory results, and chest CT findings of 45 adult patients with COVID-19 (COVID-19 group) and 55 adult patients with MP (MP group) were reviewed retrospectively. All of the patients were diagnosed in the public hospitals in the epidemic area from 20 January to 28 February 2020.

 Muscle ache and fatigue were more frequently present in the COVID-19 group (P = 0.009 and 0.029, respectively). Increased procalcitonin levels were more common in the MP group (P = 0.001). The chest CT results indicated that bilateral lung involvement, ground glass opacities, “crazy-paving” patterns, and air bronchogram signs were more common in the COVID-19 group (P < 0.001 for all), respectively. However, single lobe involvement, pulmonary consolidations, lobular central nodules, generalized bronchial wall thickening with luminal stenosis, and bronchial mucus impaction were more common in the MP group (P < 0.001 for all). Receiver operating characteristic analysis of a model established using CT parameters indicated a good or excellent performance in distinguishing COVID-19 from MP.

 COVID-19 and MP have similar clinical manifestations and laboratory results in early stage. However, the chest CT findings are valuable in the differential diagnosis of these two diseases, particularly in patients from COVID-19 epidemic areas.

Mycoplasma pneumoniae is one of the widespread causes of community-acquired pneumonia (CAP). Over recent years, the widespread use of macrolides has led to the emergence of macrolide-resistant M. pneumoniae (MRMP) resulted from mutations at specific positions of domain V of the 23S rRNA gene.

We collected 100 samples of throat swabs from patients with respiratory infections. After extraction of DNA from bacterial cell cultured in PPLO broth media using Roche kit (Germany), the PCR was performed on specific samples of M. pneumoniae using specific primers for 23S rRNA gene. Afterwards, for positive samples, minimum inhibitory concentration (MIC) was determined using the broth microdilution with Clarithromycin. Finally, the PCR product was sequenced to detect mutations related to macrolide resistance in domain V of 23S rRNA.

According to the analysis of the sequenced PCR product of M. pneumoniae 23S rRNA gene using Clustalw2 online software, one of the samples were shown to have a mutation at A2431G and G2491A positions. The MIC measurement also revealed that all isolates were sensitive to Clarithromycin, and there was no macrolide resistance to Clarithromycin in all isolates.

Sequence analysis of the 23S rRNA gene in M. pneumoniae, revealed no macrolide resistance of M. pneumoniae to Clarithromycin. Thus, the use of these antibiotics should be restricted to prevent the development of macrolide-resistant M. pneumoniae in Iran.

Mycoplasma pneumoniae (M. pneumoniae) is an important cause of community-acquired pneumonia (CAP) in children.

This study investigated the epidemiological characteristics of hospitalized children with Mycoplasma pneumoniaepneumonia (MPP) in Hangzhou.

M. pneumoniae 16s rRNA in respiratory tract sample of children was detected by SAT-MP assay from July 1, 2015 to June 30, 2019.

71,965 samples were tested by SAT-MP (simultaneous amplification and testing of Mycoplasma pneumonia) assay, 10206 (14.2%) were positive for M. pneumoniae. The highest positive rate of M. pneumoniae infection in the second half year appeared in 2015 reaching 24.3% and the lowest appeared in 2017 dropping to 9.8%. The detected monthly positive rates of M. pneumoniae infection ranged from 8.2% to 25.5%, with a peak in August. The positive rate of M. pneumoniae infection increased with the age and it reached the peak in children older than 5 years.

This large samples study revealed that the M. pneumoniae positive rate was higher in older hospitalized children and it reached the highest point in summer in terms of prevalence in Hangzhou.

Extrapulmonary complications of Mycoplasma pneumoniae (M. pneumoniae) infection include encephalitis, optic neuritis, acute psychosis, stroke, cranial nerve palsies, aseptic meningitis and also it may be implicated in immune mediated neurological diseases such as acute demyelinating encephalomyelitis, Guillain-Barre syndrome and transverse myelitis. We present five cases with acute neurological diseases after M. pneumoniae infection. The clinical presentations were characterized by encephalitis in 2 patients, Gullain-Barre syndrome in 2 patients, transverse myelitis in 1 patient. M. pneumoniae infection was detected in serum by serological method. Only two patients had respiratory symptoms preceding M. pneumoniae infection. Brain MRI revealed hyperintensities on corpus striatum and mesencephalon in one patient with encephalitis, the other had front parietal coalescent periventricular white matter lesions on T2 images. The patient with transverse myelitis had cervical, dorsal and lumbar scattered hyperintense lesions on T2 images. Two patients were treated with high dose steroid, the other two patients received treatment with intravenous immune globuline. M. pneumoniae may reveal different neurologic complications with different radiologic findings.

The clinical spectrum of Mycoplasma pneumoniae CNS diseases had a wide range. Encephalitis and meningoencephalitis are the most frequent neurological manifestations, but cases of optic neuritis, transverse myelitis, Guillain-Barré syndrome (GBS), etc. have been reported. To determine the role of M. pneumonia (using PCR and serologically test) in Cerebro Spinal Fluid (CSF) in febrile children with neurologic manifestations (in comparison with normal CSF).. This cross sectional study was done in pediatric wards of Rasoul hospital in Tehran between 2008 - 2010 upon 55 febrile cases with neurological signs and 10 controls with normal CSF (simple febrile seizure). The CSF samples tested for M. pneumonia DNA (PCR); and Immune Globulin G (IgG) level. Chi square values < 0.05 were considered statistically significant.. Positive PCR found in 1 case with Guillan Barre syndrome (1/53; 2%) and none of controls; IgG-CSF level (Cut off 0.0025) had significant difference between cases and controls (Kappa = 0.27, P Value = 0.000). The lowest and highest IgG level observed in aseptic meningitis, and convulsive cases respectively. 73% sensitivity; 90% specificity; 100% Variance (PPV); 28.8% Net Present Value (NPV) determined for IgG-CSF test.. Even, very low amount of CSF-IgG with good specificity (90%); could differentiate cases and controls (P = 0.000). The CSF-IgG test (sensitivity 70%, NPV 28.8%) was weak for ruling out the M. pneumonia in cases. positive PCR was rare (2%) in CSF of cases and controls but is more reliable for diagnosing the recent M. pneumonia infection. We prefer to assay the CSF for both serology and PCR in highly suspicious cases. Anti-microbial or immune modulating therapies had possible benefits..